Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer's Disease

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Alzheimer's disease, a condition that affects memory and thinking skills. The study will evaluate a treatment called ABBV-916, which is a special type of protein known as a monoclonal antibody. This protein is designed to target and reduce certain harmful substances in the brain associated with Alzheimer's disease. The trial will also involve a comparison with a placebo, which is a substance with no active medication, to see how effective the treatment is.

The purpose of the study is to assess the safety and effectiveness of ABBV-916 in people with early stages of Alzheimer's disease. Participants will receive the treatment through an injection into a vein, known as an intravenous injection. The study will monitor how the treatment affects the brain over time, particularly looking at changes in brain substances linked to Alzheimer's disease. Another medication, MK-6240, will be used to help measure these changes in the brain.

Throughout the study, participants will have regular check-ups and brain scans to track their progress. The study aims to provide valuable information on whether ABBV-916 can help reduce the harmful substances in the brain and improve symptoms in people with early Alzheimer's disease. This research is important for developing new treatments that could potentially slow down or improve the condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial's purpose, procedures, and potential risks and benefits. You will be asked to provide consent to participate.

    You will undergo initial assessments to confirm eligibility, including tests to evaluate your memory and thinking abilities, as well as imaging tests to check for specific brain changes associated with Alzheimer's disease.

  2. Step 2

    Initial treatment phase

    If eligible, you will be randomly assigned to receive either the study medication ABBV-916 or a placebo. A placebo is a substance with no active medication, used for comparison.

    The medication will be administered as a solution for injection through a vein, known as an intravenous injection. The frequency and dosage will be determined by the study protocol.

  3. Step 3

    Ongoing treatment and monitoring

    You will receive repeated intravenous administrations of the study medication over a specified period. The primary goal is to evaluate the safety and effects of the medication on brain changes related to Alzheimer's disease.

    Regular visits will be scheduled to monitor your health, assess the medication's effects, and perform necessary tests, including brain scans and cognitive assessments.

  4. Step 4

    Evaluation of treatment effects

    At week 24, a key assessment will be conducted to measure changes in brain amyloid plaque deposition using a specialized imaging test called an amyloid PET scan.

    This evaluation will help determine the effectiveness of the study medication in reducing amyloid plaques, which are associated with Alzheimer's disease.

  5. Step 5

    Completion of the study

    Upon completing the study, you will undergo final assessments to evaluate your overall health and any changes in your condition.

    You will receive information about the study's findings and any potential next steps regarding your treatment and care.

Who can join the trial?

5 criteria

  • Adult male or female, aged between 50 and 90 years old.
  • Must have, in the investigator's opinion, adequate ability to read and write, and good enough vision or hearing to complete the required tests.
  • Must have a score between 20 and 28 on the MMSE test at the start of the study. The MMSE is a test that checks memory and thinking skills.
  • Must have a blood test result that suggests the presence of amyloid, a protein linked to Alzheimer's disease.
  • Must have a brain scan result that shows amyloid buildup, with a specific measurement called a centiloid value of 37 or higher. This is determined by a visual assessment of the scan.

Who cannot join the trial?

3 criteria

  • Patients who do not have a diagnosis of Alzheimer's disease cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, which means they might need special protection, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

ABBV-916 is a medication being studied for its potential to help people with early Alzheimer's disease. Alzheimer's disease is a condition that affects the brain and can lead to memory loss and other cognitive problems. ABBV-916 is given through an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The main goal of using ABBV-916 in this study is to see if it can safely reduce the amount of amyloid in the brain. Amyloid is a protein that can build up in the brains of people with Alzheimer's disease and is thought to play a role in the development of the condition. By reducing amyloid levels, ABBV-916 may help slow down the progression of Alzheimer's disease and improve symptoms.

What is already known about the treatment

ABBV-916 – ABBV-916 is administered through an intravenous infusion, meaning it is delivered directly into the bloodstream via a vein. Currently, this medication is being studied in clinical trials to assess its safety and effectiveness for treating early Alzheimer's disease, a condition that affects memory and cognitive function. The main goal of ABBV-916 is to reduce amyloid plaques in the brain, which are believed to contribute to the progression of Alzheimer's disease. It belongs to a class of drugs known as monoclonal antibodies, which are designed to target specific proteins in the body.

Investigated diseases

Alzheimer's disease – Alzheimer's disease is a progressive neurological disorder that affects the brain, leading to memory loss and cognitive decline. It typically begins with mild memory lapses and confusion, which gradually worsen over time. As the disease progresses, individuals may experience difficulties with language, disorientation, mood swings, and behavioral changes. In advanced stages, individuals may lose the ability to carry out daily activities and require full-time care. The disease is characterized by the accumulation of amyloid plaques and tau tangles in the brain, which disrupt communication between nerve cells. This disruption leads to the death of brain cells and a decline in brain function.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-500691-59-00Protocol codeM22-721Estimated enrolment184 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).